title: [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
abstract: OBJECTIVE
  To evaluate the efficacy of rituximab (RT) in cryoglobulinemic vasculitis (CGV) and MALT lymphomas of the parotid gland (PG) in patients with Sjögren's disease (SD).
  
  
  METHODS
  RT therapy was performed in 13 patients with SD and CGV and in 17 with SD and PC MALT lymphoma. Eleven patients with SD received RT monotherapy and 19 with this disease had combined therapy with RT and cyclophosphan (CP). RT was used intravenously dropwise at a dose of 500 mg weekly or once every two weeks in combination with intravenous dropwise CP 1000 mg the next day with 4-6 per course. For the diagnosis of MALT lymphomas, all the patients with SD underwent incisional PG biopsy under local anesthesia at the Research Institute of Rheumatology, Russian Academy of Medical Sciences. PG biopsy specimens were histologically and immunohistochemically studied at the Russian Cancer Research Center, Russian Academy of Medical Sciences. In 11 cases, B-cell clonality was identified from immunoglobulin (Ig) heavy chain genes rearrangements, by using polymerase chain reaction at the Hematology Research Center, Ministry of Health and Social Development of the Russian Federation.
  
  
  RESULTS
  Cutaneous manifestations of vasculitis disappeared in 75% of cases after monotherapy with RT and in 100% of cases after combination therapy with RT and CP. At 6-month follow-up, a complete response to therapy remained in 25% of the patients after a course of monotherapy and in 83% after combined therapy. Serum monoclonal Ig cryoglobulins and their urinary light chains ceased to be detectable in 75% of the patients in both groups at 3 months. At 6 months, a recurrence of mixed monoclonal cryoglobulinemia was seen in 50 and 43% of cases after monotherapy and combined therapy, respectively. The clinical and laboratory response of cryoglobunemic glomerulonephritis to combined therapy with RT and CP was complete in 60% of cases at 6-month follow-up. After RT monotherapy, the patients with SD and PG MALT lymphoma achieved a complete clinical response in 88%, of whom histological and immunohistochemical reexaminations of PG biopsy specimens revealed no signs of MALT lymphoma in 71% of cases. B-cell clonality remained in the PG biopsy specimens following RT monotherapy. After the combination of RT and CP, a complete clinical response to therapy was observed in 100% of the patients, a complete histological response and a complete molecular one were seen in 83 and 60%, respectively.
  
  
  CONCLUSIONS
  RT showed its efficacy in treating SD patients with CGV and PG MALT lymphomas.
authors.forename: O A
authors.initials: OA
authors.lastname: Logvinenko
authors.forename: V I
authors.initials: VI
authors.lastname: Vasil'ev
authors.forename: S Kh
authors.initials: SKh
authors.lastname: Sedyshev
authors.forename: T N
authors.initials: TN
authors.lastname: Safonova
authors.forename: E B
authors.initials: EB
authors.lastname: Rodionova
authors.forename: N V
authors.initials: NV
authors.lastname: Kokosadze
authors.forename: E N
authors.initials: EN
authors.lastname: Aleksandrova
authors.forename: M V
authors.initials: MV
authors.lastname: Cherkasova
authors.forename: S G
authors.initials: SG
authors.lastname: Radenska-Lopovok
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D001706:Biopsy; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000032:analysis; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D015166:Monitoring, Immunologic / Q000379:methods; D010306:Parotid Gland / Q000276:immunology / Q000473:pathology; D010307:Parotid Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000473:pathology; D012074:Remission Induction; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications*; D056647:Systemic Vasculitis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007143:Immunoglobulin Heavy Chains; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide